Abstract Book - PDF - San Antonio Breast Cancer Symposium

CTRC-AACR San Antonio Breast Cancer Symposium
Tumor Cell and Molecular Biology: Angiogenesis
P1-06-01 Upregulation of metabolism as a potential resistance
mechanism to bevacizumab in primary breast cancer
Mehta S, Hughes NP, Adams RF, Li SP, Han C, Kaur K, Taylor NJ,
Padhani AR, Makris A, Buffa FM, Harris AL. Weatherall Institute of
Molecular Medicine, Oxford, United Kingdom; Stanford University,
Stanford, CA; Oxford University Hospitals NHS Trust, Oxford, United
Kingdom; Mount Vernon Cancer Centre, Northwood, Middlesex,
United Kingdom; Cancer and Haematology Centre, Churchill
Hospital, Oxford, United Kingdom; Paul Strickland Scanner Centre,
Mount Vernon Hospital, Northwood, Middlesex, United Kingdom.
P1-06-02 A newly angiogenic biomarker Vasohibin-1 expression in
ductal carcinoma in situ of the breast
Tamaki K, Tamaki N, Kamada Y, Uehara K, Miyashita M, Ishida T,
Ohuchi N, Sasano H. Nahanishi Clinic Okinawa, Naha, Okinawa,
Japan; Tohoku University Graduate School of Medicine, Sendai,
Miyagi, Japan; Tohoku University Hospital, Sendai, Miyagi, Japan.
P1-06-03 Microvessel density as determined by computerized image
analysis of CD34 and CD105 expression correlates with poor
outcome in triple-negative breast cancer
De Brot M, Rocha RM, Soares FA, Gobbi H. Universidade Federal de
Minas Gerais, Belo Horizonte, MG, Brazil; Hospital A.C. Camargo, Sao
Paulo, SP, Brazil.
Prognostic and Predictive Factors: Biomarkers - Methods
P1-07-01 Attainment of extremely high concordance rates between
fluorescence in situ hybridization and immunohistochemistry
in testing for human epidermal growth factor receptor 2
(HER2) in breast cancer using a normalized scoring system for
immunohistochemistry: A four year experience with over
9000 cases
Gown AM, Goldstein LC, Tse CH, Hwang HC, Kandalaft PL. PhenoPath
Laboratories, Seattle, WA.
P1-07-02 Withdrawn
P1-07-03 Quantification of HER2 expression at the single cell level
and HER2 intratumoral heterogeneity of breast cancer tissue
samples using automated image analysis
Geretti E, Paragas V, Onsum M, Kudla A, Moulis S, Luus L, Wickham T,
McDonagh C, MacBeath G, Hendriks B. Merrimack Pharmaceuticals,
Cambridge, MA.
P1-07-04 Comparison of HER2 expression by immunohistochemistry
(IHC) using automated imaging system and fluorescence in
situ hybridization (FISH). A retrospective analysis of
2853 cases
Collins R, Xiang D, Christie A, Leitch M, Euhus D, Rao R, Haley B,
Sarode V. University of Texas Southwestern Medical Center,
Dallas, TX.
P1-07-05 Evaluation of tissue processing factors affecting HER2 IHC
staining intensity in breast cancer cell lines
Jensen K, Erickson J, Webster S, Pedersen HC. Dako Denmark,
Glostrup, Denmark; Dako North America, Carpinteria, CA.
P1-07-06 Effect of biospecimen variables on proteomic biomarker
assessment in breast cancer
Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci
S, Adrada B, Singh G, Anh-Do K, Garces Z, Mittendorf EA, Babiera G,
Wagner J, Bedrosian I, Krishnamurthy S, Symmans WF, Gonzalez-
Angulo AM, Mills G. UT MD Anderson Cancer Center, Houston, TX;
Ohio State University, Columbus, OH.
P1-07-07 Inflammatory gene expression variations in the interval
between core needle biopsy and excisional biopsy in early
breast cancer
Jeselsohn RM, Regan MM, Werner L, Fatima A, He HH, Brown M,
Iglehart JD, Richardson AL, Come S. Beth Israel Deaconess Medical
Center, Boston, MA; Dana Farber Cancer Institute, Boston, MA;
Brigham and Women’s Hospital, Boston, MA.
P1-07-08 Effect of sample preservation method and transportation
duration on tumor gene expression profiling in breast cancer
Fumagalli D, Jose V, Salgado R, Majjaj S, Singhal S, Vincent D,
Maetens M, Larsimont D, Symmans F, Dinh P, Piccart M, Michiels
S, Sotiriou C, Loi S. Institut Jules Bordet, Brussels, Belgium; Breast
International Group (BIG), Brussels, Belgium; The University of Texas
MD Anderson Cancer Center, Houston, TX.
P1-07-09 Estrogen receptor positivity: 10% or 1%?
Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM,
Bedrosian I, Symmans WF, Hortobagyi GN, Crow JR, Shah RR, Hunt
KK. University of Texas MD Anderson Cancer Center, Houston, TX.
P1-07-10 Comparison of three commercial ER/PR assays on a single
clinical outcome series
Kornaga EN, Klimowicz AC, Konno M, Guggisberg N, Ogilvie T,
Cartun RW, Morris DG, Webster MA, Magliocco AM. Alberta Health
Services, Calgary, AB, Canada; Calgary Laboratory Services, Calgary,
AB, Canada; Hartford Hospital, Hartford, CT; University of Calgary, AB,
Canada; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
P1-07-11 Characterization of progesterone receptor biomarker for
predicting antiprogestin activity in human cancers
Bonneterre J, Bosq J, Lange C, Gilles E. Centre Oscar Lambret, France;
Institut Gustave Roussy, France; University of Minnesota; Invivis
Pharmaceuticals.
P1-07-12 Using Natural Language Processing to Identify and Extract
HER2 Value from a large EMR system
Zheng C, Avila C, Haque R. Kaiser Permanente Southern California,
Pasadena, CA.
P1-07-13 Prognostic relevance of statistically standardized estrogen
receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2) in tamoxifen(TAM)-
treated NCIC CTG MA.14 patients
Chapman J-AW, Sgroi D, Goss PE, Richardson E, Binns SN, Zhang Y,
Schnabel CA, Erlander MG, Pritchard KI, Han L, Shepherd LE, Pollak
MN. NCIC Clinical Trials Group, Queen’s University, Kingston, ON,
Canada; Harvard University, Boston, MA; bioTheranostics, Inc., San
Diego, CA; Sunnybrook Odette Cancer Centre, University of Toronto,
ON, Canada; Jewish General Hospital, McGill University, Montreal,
QC, Canada.
P1-07-14 Enabling biomarker validation in breast cancer molecular
subtypes: sensitivity and specificity of array-based subtype
classification in 983 patients
Györffy B, Lanczky A. Semmelweis University.
P1-07-15 Revisiting chromosome 17q copy number aberrations in early
high-risk breast cancer
Kotoula V, Bobos M, Eleftheraki AG, Timotheadou E, Razis E, Goussia
A, Levva S, Kalogeras KT, Pectasides D, Fountzilas G. Hellenic
Cooperative Oncology Group (HeCOG), Athens, Greece.
P1-07-16 Liver derived epithelial cells as source of false positive
circulating tumor cells in early breast cancer
Habets L, Körber W, Frenken B, Danaei M, Kusche M, Peisker U, Kroll
T, Pachmann K. Metares.e.V, Aachen, NRW, Germany; Brustzentrum
Aachen Kreis Heinsberg, Aachen, NRW, Germany; Medizinische
Universitätsklinik Jena, Thueringen, Germany.
P1-07-17 V Array: A novel tool for constructing virtual tissue
microarrays (TMAs), an evaluation of its use in optimizing TMA
construction for Ductal Carcinoma in Situ (DCIS)
Quintayo MA, Starczynski J, Yan FJ, Bartlett JMS, Benko L, Hanna W,
Nofech-Mozes S, Rakovitch E. Ontario Institute of Cancer Research,
Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto,
ON, Canada; Leica Microsystems, Buffallo Grove, IL.
Cancer Res; 72(24 Suppl.) December 15, 2012 12s Cancer Research